Respiratory disease
The substantial socioeconomic burden of lung diseases, recently highlighted by the disastrous impact of the coronavirus disease 2019 (COVID-19) pandemic, accentuates the need for interventive treatments capable of decelerating disease progression, limiting organ damage, and contributing to a functional tissue recovery. However, this is hampered by the lack of accurate human lung research models, which currently fail to reproduce the human pulmonary architecture and biochemical environment. Stellixir offers Induced pluripotent stem cells (iPSCs) based drug discovery services which possess suitable characteristics for the generation of physiologically relevant in vitro lung models, allowing for developmental studies, disease modelling, and toxicological screening. Stellixir Biotech has significant experience in respiratory disease research. Our research scientists have facilitated our clients for potential drug discoveries, enabling them to develop the drug from early discovery to the development of therapeutics.
Discovery Services:
- Human Primary cell-based assays- Using 2D and 3D disease-relevant models
- High Content Screening- Using standard cell model and disease-related cell lines.
- Inhalation toxicity test
- Anti-viral studies
- In-vitro 3D respiratory models- for drug testing, inhalation toxicity, viral infections and inflammation studies
- 3D mucociliary tissue model - human-derived nasal/bronchial epithelial cells
- The 3D model derived from basal cells, goblet cells and ciliated cells
Available Models:
- Monoculture using primary epithelial cells
- Co-Culture with endothelial cells
- Tri-culture with fibroblasts
- In-vitro 3D respiratory models-
- 3D mucociliary tissue model - human-derived nasal/bronchial epithelial cells
- The 3D model derived from basal cells, goblet cells and ciliated cells
Techniques Used: Flow Cytometry, Confocal/Fluorescence Microscopy (Multi-colour Immunofluorescence), ELISA (Fluorimetry/Colorimetry), RTqPCR, WB.